JP6494527B2 - 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原 - Google Patents

肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原 Download PDF

Info

Publication number
JP6494527B2
JP6494527B2 JP2015557089A JP2015557089A JP6494527B2 JP 6494527 B2 JP6494527 B2 JP 6494527B2 JP 2015557089 A JP2015557089 A JP 2015557089A JP 2015557089 A JP2015557089 A JP 2015557089A JP 6494527 B2 JP6494527 B2 JP 6494527B2
Authority
JP
Japan
Prior art keywords
pneumococcal
antigen
polypeptide
cells
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015557089A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509011A (ja
JP2016509011A5 (enExample
Inventor
リチャード マリー
リチャード マリー
インジェ ルー
インジェ ルー
ファン チャン
ファン チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Children's Hospital
Original Assignee
Boston Children's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Children's Hospital filed Critical Boston Children's Hospital
Publication of JP2016509011A publication Critical patent/JP2016509011A/ja
Publication of JP2016509011A5 publication Critical patent/JP2016509011A5/ja
Priority to JP2019039100A priority Critical patent/JP6916828B2/ja
Application granted granted Critical
Publication of JP6494527B2 publication Critical patent/JP6494527B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015557089A 2013-02-07 2014-02-07 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原 Active JP6494527B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019039100A JP6916828B2 (ja) 2013-02-07 2019-03-05 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361762062P 2013-02-07 2013-02-07
US61/762,062 2013-02-07
PCT/US2014/015254 WO2014124228A1 (en) 2013-02-07 2014-02-07 Protein antigens that provide protection against pneumococcal colonization and/or disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019039100A Division JP6916828B2 (ja) 2013-02-07 2019-03-05 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原

Publications (3)

Publication Number Publication Date
JP2016509011A JP2016509011A (ja) 2016-03-24
JP2016509011A5 JP2016509011A5 (enExample) 2017-03-09
JP6494527B2 true JP6494527B2 (ja) 2019-04-03

Family

ID=51300148

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015557089A Active JP6494527B2 (ja) 2013-02-07 2014-02-07 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
JP2019039100A Active JP6916828B2 (ja) 2013-02-07 2019-03-05 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019039100A Active JP6916828B2 (ja) 2013-02-07 2019-03-05 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原

Country Status (7)

Country Link
US (3) US11576958B2 (enExample)
EP (2) EP4272750A3 (enExample)
JP (2) JP6494527B2 (enExample)
AU (2) AU2014214844B2 (enExample)
CA (2) CA3247431A1 (enExample)
ES (1) ES2959258T3 (enExample)
WO (1) WO2014124228A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2632651C2 (ru) 2011-05-11 2017-10-06 Чилдрен'С Медикал Сентер Корпорейшн Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
US11058757B2 (en) 2016-03-31 2021-07-13 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CN110392690B (zh) * 2017-02-24 2024-01-30 默沙东有限责任公司 肺炎球菌缀合物疫苗制剂
EP3600400A4 (en) 2017-03-28 2021-01-13 The Children's Medical Center Corporation MULTIPLE ANTIGEN (MAPS) BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGENIC COMPOSITION AND USES THEREOF
WO2018183666A1 (en) * 2017-03-31 2018-10-04 Boston Medical Center Corporation Methods and compositions using highly converved pneumococcal surface proteins
WO2018217564A1 (en) * 2017-05-22 2018-11-29 The Children's Medical Center Corporation Combined vaccine against mycobacterium tuberculosis
SG11201912601RA (en) 2017-06-23 2020-01-30 Nosocomial Vaccine Corp Immunogenic compositions
HUE068482T2 (hu) 2017-09-07 2025-01-28 Merck Sharp & Dohme Llc Pneumococcus-poliszacharidok és azok felhasználása immunogén poliszacharid-hordozóprotein konjugátumokban
EP3691677A4 (en) 2017-10-04 2021-07-07 Pogona, Llc COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE
GB201807303D0 (en) 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
GB201807380D0 (en) 2018-05-04 2018-06-20 Karlsson Roger Biomarkers for detecting microbial infection
EP3847246A1 (en) * 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
CN113164580B (zh) * 2018-09-12 2025-06-10 儿童医疗中心公司 肺炎球菌融合蛋白疫苗
CA3173301A1 (en) * 2020-03-03 2021-09-10 Mayo Foundation For Medical Education And Research Zika virus polypeptides
KR20220018939A (ko) * 2020-08-07 2022-02-15 (주)셀트리온 폐렴구균 다당류-세포벽 유래 물질 접합체를 포함하는 면역원성 조성물
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.
WO2024192346A1 (en) * 2023-03-16 2024-09-19 Affinivax, Inc. Immunogenic compositions
WO2024229176A1 (en) 2023-05-04 2024-11-07 Affinivax, Inc. Rhizavidin variants
WO2025193903A1 (en) 2024-03-15 2025-09-18 Affinivax, Inc. Pneumococcal polysaccharide compositions and uses thereof
WO2026064840A1 (en) * 2024-09-30 2026-04-02 Celosia Therapeutics Pty Ltd Proteinaceous molecules and uses therefor

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB1502774A (en) 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4242501A (en) 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
DE3413608A1 (de) 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4686102A (en) 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DE3779909T2 (de) 1986-03-06 1993-01-07 Commw Scient Ind Res Org In-vitro-testverfahren zum nachweis zellulaerer immunresponsen.
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
GB8906795D0 (en) 1989-03-23 1989-05-10 Carroll Noel Method of preparing vaccines
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0372423A (ja) 1989-05-26 1991-03-27 Green Cross Corp:The パーフルオロカーボン化合物含有乳化製剤
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5371197A (en) 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5674698A (en) 1992-09-14 1997-10-07 Sri International Up-converting reporters for biological and other assays using laser excitation techniques
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
DE69628418T2 (de) 1995-03-22 2004-04-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
ES2301175T3 (es) 1996-02-09 2008-06-16 Smithkline Beecham Biologicals S.A. Vacunas contra el producto del gen 63 del virus de la varicela zoster.
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
ATE348887T1 (de) * 1996-10-31 2007-01-15 Human Genome Sciences Inc Streptococcus pneumoniae antigene und impfstoffe
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ES2230687T3 (es) 1997-04-24 2005-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Copulacion de proteinas nomodificadas con polisacaridos derivados de haloacilo o de dihaloacilo para la preparacion de vacunas que incluyen proteinas-polisacaridos.
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
AU740956B2 (en) 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
WO1999012416A1 (en) 1997-09-09 1999-03-18 The Trustees Of Columbia University In The City Of New York T-independent conjugate-vaccines
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
WO2000006737A2 (en) * 1998-07-27 2000-02-10 Microbial Technics Limited Streptococcus pneumoniae proteins and nucleic acid molecules
EP1144640A3 (en) * 1998-07-27 2001-11-28 Microbial Technics Limited Nucleic acids and proteins from streptococcus pneumoniae
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CA2355364C (en) 1998-12-21 2014-03-18 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
GB9928678D0 (en) 1999-12-03 2000-02-02 Provalis Uk Ltd Streptococcus pneumoniae antigens
US6398774B1 (en) 1999-09-29 2002-06-04 Heska Corporation Intranasal delivery system
US8246945B2 (en) 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
EP2292632A3 (en) 2000-09-26 2012-07-25 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
SE0003538D0 (sv) 2000-09-29 2000-09-29 Isconova Ab New immunogenic complex
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
WO2003044185A2 (en) 2001-11-21 2003-05-30 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in general metabolism
NZ536859A (en) 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US20060121058A1 (en) 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
CN100443116C (zh) 2002-11-07 2008-12-17 新纳几美国公司 治疗或预防肺炎球菌感染的组合物及其用途
AU2002952548A0 (en) 2002-11-08 2002-11-21 Cellestis Limited Diagnostic assay
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
US7635487B2 (en) 2003-04-15 2009-12-22 Intercell Ag S. pneumoniae antigens
WO2005004909A2 (en) 2003-05-07 2005-01-20 Aventis Pasteur, Inc. Method of enhanced immunogenicity to meningococcal vaccination
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
GB0318688D0 (en) 2003-08-08 2003-09-10 Chiron Srl Streptococcus pneumoniae knockout mutants
WO2005037190A2 (en) 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Multiplex vaccines
US20050214318A1 (en) 2003-10-23 2005-09-29 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on fusion protein
US20050181035A1 (en) 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US20050226899A1 (en) 2004-04-08 2005-10-13 Mauro Castiglioni Cosmetic mask composition
EP1740604A2 (en) 2004-04-27 2007-01-10 Intercell AG Td antigens
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
JP2008509682A (ja) 2004-08-18 2008-04-03 ガヴァナーズ オブ ザ ユニヴァーシティー オブ アルバータ Ｙｅｂｆを利用するタンパク質の製造方法
FI20041396A0 (fi) 2004-10-29 2004-10-29 Vesa Pekka Hytoenen Uudet mikrobiavidiinit
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
ES2433467T3 (es) 2005-01-20 2013-12-11 Isconova Ab Composición de vacuna que comprende una proteína de unión a fibronectina o un péptido de unión a fibronectina
CA2597489A1 (en) 2005-02-11 2006-08-17 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides
US20090148894A1 (en) 2005-08-15 2009-06-11 Broedel Sheldon E Methods for optimizing the secretion of protein in prokaryotes
CN102973929B (zh) 2005-09-01 2017-04-26 诺华疫苗和诊断有限两合公司 含血清群c脑膜炎球菌的多价疫苗
EP1973572A2 (en) 2005-12-08 2008-10-01 University of Louisville Research Foundation, Inc. In vivo cell surface engineering
WO2007081583A2 (en) 2006-01-04 2007-07-19 Children's Medical Center Corporation Anti-pneumococcal preparations and methods of use
US7943133B2 (en) 2006-02-02 2011-05-17 Boston Biocom Llc Mesothelin antibody protein fusions and methods of use
EP1988918A4 (en) 2006-02-22 2010-04-28 Novavax Inc ADJUVANZ AND VACCINE COMPOSITIONS
US20080032340A1 (en) 2006-06-09 2008-02-07 University Of Arizona Peptide motifs for binding avidin or neutravidin
US8148084B2 (en) 2006-06-22 2012-04-03 Dana-Farber Cancer Institute, Inc. Diagnosis of autoimmune disease
WO2007150020A1 (en) 2006-06-23 2007-12-27 Simon Paul M Targeted immune conjugates
US7452985B2 (en) 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
AU2007342333B2 (en) 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
US20090022760A1 (en) 2006-09-12 2009-01-22 Alphavax Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants
US20090047255A1 (en) 2006-11-03 2009-02-19 Alphavax, Inc. Alphavirus and Alphavirus Replicon Particle Formulations and Methods
WO2008061243A2 (en) 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
EP2104512A2 (en) 2006-12-21 2009-09-30 Emergent Product Development UK Limited Streptococcus proteins, and their use in vaccination
CN100579152C (zh) 2007-01-29 2010-01-06 华为技术有限公司 一种播放集团彩铃的方法、系统及装置
KR101491867B1 (ko) 2007-01-31 2015-02-10 피페넥스 인크. 증가된 발현을 위한 박테리아 리더 서열
WO2008119358A2 (en) 2007-03-30 2008-10-09 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides for use in vaccine compositions
AU2008287286B2 (en) 2007-04-13 2013-10-10 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
EA200901578A1 (ru) 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009021548A1 (en) 2007-08-10 2009-02-19 Wacker Chemie Ag Expression of full length igg and secretion into the culture medium of prokaryotic cells
KR20100072228A (ko) 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US20090068288A1 (en) 2007-09-07 2009-03-12 Wayne Kruger Topical antiseptic veterinary solution
EP2293815A4 (en) * 2008-05-22 2013-04-03 Childrens Medical Center SYNERGISTIC IMMUNOGENIC FUSION PROTEIN POLYSACCHARIDE CONJUGATE
CA2781805A1 (en) 2008-12-17 2010-07-08 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
CN106008679A (zh) 2008-12-24 2016-10-12 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 修饰的肺炎链球菌溶血素(ply)多肽
EP2208787A1 (en) 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
RU2585961C9 (ru) 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
JP5931724B2 (ja) 2009-06-29 2016-06-08 ジェノセア バイオサイエンシーズ， インコーポレイテッド ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物
WO2011044576A2 (en) 2009-10-09 2011-04-14 Children's Medical Center Corporation Selectively disrupted whole-cell vaccine
EP2335721A1 (en) 2009-12-21 2011-06-22 Institut Pasteur Streptavidin and Biotin-based antigen delivery system
US20110159040A1 (en) 2009-12-30 2011-06-30 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
US20130115230A1 (en) 2010-04-30 2013-05-09 Augmenta Biologicals, Llc Delivery proteins
CA2849391A1 (en) 2010-10-20 2012-04-26 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
SG10201600435UA (en) 2011-01-20 2016-02-26 Genocea Biosciences Inc Vaccines And Compositions Against Streptococcus Pneumoniae
RU2632651C2 (ru) 2011-05-11 2017-10-06 Чилдрен'С Медикал Сентер Корпорейшн Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
US9765125B2 (en) 2012-01-20 2017-09-19 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against Streptococcus pneumoniae
WO2014018904A1 (en) 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
KR20250058066A (ko) 2015-07-21 2025-04-29 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
CN113164580B (zh) 2018-09-12 2025-06-10 儿童医疗中心公司 肺炎球菌融合蛋白疫苗

Also Published As

Publication number Publication date
JP6916828B2 (ja) 2021-08-11
US11576958B2 (en) 2023-02-14
ES2959258T3 (es) 2024-02-22
AU2014214844B2 (en) 2017-12-14
AU2018201768A1 (en) 2018-04-05
JP2016509011A (ja) 2016-03-24
EP4272750A2 (en) 2023-11-08
EP2953638B1 (en) 2023-07-05
EP2953638A1 (en) 2015-12-16
CA3247431A1 (en) 2026-03-02
AU2014214844A1 (en) 2015-08-13
WO2014124228A1 (en) 2014-08-14
US20230081705A1 (en) 2023-03-16
JP2019108375A (ja) 2019-07-04
EP2953638A4 (en) 2016-08-03
CA2900008C (en) 2025-10-07
US20250114443A1 (en) 2025-04-10
US12083173B2 (en) 2024-09-10
EP4272750A3 (en) 2024-01-24
CA2900008A1 (en) 2014-08-14
US20150374811A1 (en) 2015-12-31
AU2018201768B2 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
US12083173B2 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
US11207375B2 (en) Vaccines and compositions against Streptococcus pneumoniae
JP6126993B2 (ja) 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）に対するワクチン及び組成物
EP3849599A1 (en) Pneumococcal fusion protein vaccines
CN109069424B (zh) 脂质体疫苗
US20090252756A1 (en) Protein-based streptococcus pneumoniae vaccines
EP4727575A2 (en) Fusion proteins generating protective antibodies and protective th17 responses for pseudomonas aeruginosa
JP2013510188A (ja) 黄色ブドウ球菌に由来する菌血症関連抗原
TW201726164A (zh) 脂質體疫苗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181026

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190305

R150 Certificate of patent or registration of utility model

Ref document number: 6494527

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250